CD274 and non-small cell lung carcinoma: Meanwhile, in the phase 1 MK-7684–001 trial (NCT02964013), vibostolimab administered alone or in combination with pembrolizumab showed favorable safety and modest activity (ORR 5%–7%) in αPD-1/PD-L1–refractory NSCLC, while also exhibiting encouraging antitumor activity (109).